{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:18:46Z","timestamp":1740143926234,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:00:00Z","timestamp":1613606400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:00:00Z","timestamp":1613606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s11523-021-00793-7","type":"journal-article","created":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T15:07:09Z","timestamp":1613747229000},"page":"227-236","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["BRAFV600E Mutations Arising from a Left-Side Primary in Metastatic Colorectal Cancer: Are They a Distinct Subset?"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4323-8786","authenticated-orcid":false,"given":"Vanessa","family":"Wong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeanne","family":"Tie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayesh","family":"Desai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Nott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Steel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Burge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigette","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adnan","family":"Khattak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Gibbs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,18]]},"reference":[{"issue":"6","key":"793_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492.","journal-title":"CA Cancer J Clin."},{"key":"793_CR2","unstructured":"Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, et al. SEER cancer statistics review, 1975\u20132017, National Cancer Institute. Bethesda, MD. https:\/\/seer.cancer.gov\/csr\/1975_2017\/ based on November 2019 SEER data submission, posted to the SEER web site, April 2020."},{"issue":"2","key":"793_CR3","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1001\/jamaoncol.2016.3797","volume":"3","author":"S Tejpar","year":"2017","unstructured":"Tejpar S, Stintzing S, Ciardiello F, Tabernero J, Van Cutsem E, Beier F, et al. Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer. JAMA Oncol. 2017;3(2):194. https:\/\/doi.org\/10.1001\/jamaoncol.2016.3797.","journal-title":"JAMA Oncol"},{"issue":"9","key":"793_CR4","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1002\/ijc.25555","volume":"128","author":"J Tie","year":"2011","unstructured":"Tie J, Gibbs P, Lipton L, Christie M, Jorissen R, Burgess A, et al. Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAFV600E mutation. Int J Cancer. 2011;128(9):2075\u201384.","journal-title":"Int J Cancer."},{"issue":"2","key":"793_CR5","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/dcr.0b013e31823c08b3","volume":"55","author":"M Kalady","year":"2012","unstructured":"Kalady M, DeJulius K, Sanchez J, Jarrar A, Liu X, Manilic E, et al. BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis. Dis Colon Rectum. 2012;55(2):128\u201333. https:\/\/doi.org\/10.1097\/dcr.0b013e31823c08b3.","journal-title":"Dis Colon Rectum"},{"issue":"8","key":"793_CR6","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1586\/14737159.2015.1047346","volume":"15","author":"M Scartozzi","year":"2015","unstructured":"Scartozzi M, Giampieri R, Aprile G, Iacono D, Santini D, dell\u2019Aquila E, et al. The distinctive molecular, pathological and clinical characteristics of BRAF-mutant colorectal tumors. Expert Rev Mol Diagn. 2015;15(8):979\u201387. https:\/\/doi.org\/10.1586\/14737159.2015.1047346.","journal-title":"Expert Rev Mol Diagn"},{"issue":"10","key":"793_CR7","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1016\/j.ejca.2012.02.057","volume":"48","author":"C Bokemeyer","year":"2012","unstructured":"Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting M, et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer. 2012;48(10):1466\u201375.","journal-title":"Eur J Cancer."},{"issue":"3","key":"793_CR8","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/ajco.13135","volume":"15","author":"S Mendis","year":"2019","unstructured":"Mendis S, Beck S, Lee B, Lee M, Wong R, Kosmider S, et al. Right versus left sided metastatic colorectal cancer: teasing out clinicopathologic drivers of disparity in survival. Asia Pac J Clin Oncol. 2019;15(3):136\u201343. https:\/\/doi.org\/10.1111\/ajco.13135.","journal-title":"Asia Pac J Clin Oncol"},{"issue":"3","key":"793_CR9","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1002\/cam4.2747","volume":"9","author":"LC Bylsma","year":"2020","unstructured":"Bylsma LC, Gillezeau C, Garawin TA, Kelsha MA, Fryzek JP, Sangare L, et al. Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: a systematic review and meta-analysis. Cancer Med. 2020;9(3):1044\u201357. https:\/\/doi.org\/10.1002\/cam4.2747.","journal-title":"Cancer Med."},{"issue":"2","key":"793_CR10","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ygyno.2015.05.034","volume":"138","author":"R Suidan","year":"2015","unstructured":"Suidan R, Leitao M, Zivanovic O, Gardner G, Long Roche K, Sonoda Y, et al. Predictive value of the Age-Adjusted Charlson Comorbidity Index on perioperative complications and survival in patients undergoing primary debulking surgery for advanced epithelial ovarian cancer. Gynecol Oncol. 2015;138(2):246\u201351. https:\/\/doi.org\/10.1016\/j.ygyno.2015.05.034.","journal-title":"Gynecol Oncol"},{"issue":"4","key":"793_CR11","doi-asserted-by":"publisher","first-page":"264","DOI":"10.14740\/gr1062w","volume":"11","author":"B Baran","year":"2018","unstructured":"Baran B, Mert Ozupek N, Yerli Tetik N, Acar E, Bekcioglu O, Baskin Y. Difference between left-sided and right-sided colorectal cancer: a focused review of literature. Gastroenterol Res. 2018;11(4):264\u201373. https:\/\/doi.org\/10.14740\/gr1062w.","journal-title":"Gastroenterol Res"},{"issue":"12","key":"793_CR12","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1038\/bjc.2015.173","volume":"112","author":"A Rowland","year":"2015","unstructured":"Rowland A, Dias M, Wiese M, Kichenadasse G, McKinnon R, Karapetis C, Sorich M. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer. 2015;112(12):1888\u201394. https:\/\/doi.org\/10.1038\/bjc.2015.173.","journal-title":"Br J Cancer"},{"issue":"5","key":"793_CR13","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.ejca.2015.01.054","volume":"51","author":"F Pietrantonio","year":"2015","unstructured":"Pietrantonio F, Petrelli F, Coinu A, Di Bartolomeo M, Borgonovo K, Maggi C, et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer. 2015;51(5):587\u201394. https:\/\/doi.org\/10.1016\/j.ejca.2015.01.054.","journal-title":"Eur J Cancer"},{"key":"793_CR14","doi-asserted-by":"publisher","first-page":"5705","DOI":"10.1200\/JCO.2008.18.0786","volume":"26","author":"F Di Nicolantonio","year":"2008","unstructured":"Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008;26:5705\u201312.","journal-title":"J Clin Oncol"},{"key":"793_CR15","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1007\/s11033-010-0351-4","volume":"38","author":"C Mao","year":"2011","unstructured":"Mao C, Liao R, Qiu L, Wang X, Ding H, Chen Q, et al. BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis. Mol Biol Rep. 2011;38:2219\u201323. https:\/\/doi.org\/10.1007\/s11033-010-0351-4.","journal-title":"Mol Biol Rep"},{"issue":"13","key":"793_CR16","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1200\/JCO.2006.09.0928","volume":"25","author":"A Falcone","year":"2007","unstructured":"Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007;25(13):1670\u20136.","journal-title":"J Clin Oncol"},{"issue":"17","key":"793_CR17","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1403108","volume":"371","author":"F Loupakis","year":"2014","unstructured":"Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014;371(17):1609\u201318.","journal-title":"N Engl J Med"},{"issue":"13","key":"793_CR18","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/S1470-2045(15)00122-9","volume":"16","author":"C Cremolini","year":"2015","unstructured":"Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, et al. FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (mCRC): Updated survival results of the phase III TRIBE trial by the GONO group. Lancet Oncol. 2015;16(13):1306\u201315. https:\/\/doi.org\/10.1016\/S1470-2045(15)00122-9.","journal-title":"Lancet Oncol."},{"issue":"17","key":"793_CR19","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","volume":"381","author":"S Kopetz","year":"2019","unstructured":"Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N Engl J Med. 2019;381(17):1632\u201343. https:\/\/doi.org\/10.1056\/NEJMoa1908075.","journal-title":"N Engl J Med."},{"issue":"15 Suppl","key":"793_CR20","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1200\/JCO.2017.35.15_suppl.3505","volume":"35","author":"S Kopetz","year":"2017","unstructured":"Kopetz S, Mcdonough SL, Lenz HJ, Magliocco AM, Atreya CE, Diaz LA, et al. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406). J Clin Oncol. 2017;35(15_Suppl):3505.","journal-title":"J Clin Oncol."},{"key":"793_CR21","doi-asserted-by":"publisher","first-page":"S242","DOI":"10.1016\/j.annonc.2020.04.080","volume":"31","author":"A Grothey","year":"2020","unstructured":"Grothey A, Tabernero J, Taieb J, Yaeger R, Yoshino T, Maiello E, et al. LBA-5 ANCHOR CRC: a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer. Ann Oncol. 2020;31:S242\u20133.","journal-title":"Ann Oncol"},{"key":"793_CR22","doi-asserted-by":"publisher","first-page":"175883591985649","DOI":"10.1177\/1758835919856494","volume":"11","author":"M Ducreux","year":"2019","unstructured":"Ducreux M, Chamseddine A, Laurent-Puig P, Smolenschi C, Hollebecque A, Dartigues P, et al. Molecular targeted therapy of BRAF-mutant colorectal cancer. Ther Adv Med Oncol. 2019;11:1758835919856494.","journal-title":"Ther Adv Med Oncol"},{"key":"793_CR23","doi-asserted-by":"publisher","unstructured":"Andre T, Shiu K-K, Kim TW, Jensen BV, Jensen LH, Punt C, et al. (2020) Pembrolizumab vs. chemotherapy for microsatellite instability-high\/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 study.\u00a0J Clin Oncol 38(18_suppl):LBA4. https:\/\/doi.org\/10.1200\/JCO.2020.38.18_suppl.LBA4","DOI":"10.1200\/JCO.2020.38.18_suppl.LBA4"},{"issue":"12","key":"793_CR24","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1038\/bjc.2015.160","volume":"112","author":"TT Sepp\u00e4l\u00e4","year":"2015","unstructured":"Sepp\u00e4l\u00e4 TT, B\u00f6hm JP, Friman M, Lahtinen L, V\u00e4yrynen VM, Liipo TK, et al. Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer. Br J Cancer. 2015;112(12):1966\u201375.\u00a0https:\/\/doi.org\/10.1038\/bjc.2015.160.","journal-title":"Br J Cancer."},{"issue":"12","key":"793_CR25","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.6004\/jnccn.2016.0165","volume":"14","author":"CE Atreya","year":"2016","unstructured":"Atreya CE, Greene C, McWhirter RM, Ikram NS, Allen IE, Van Loon K, et al. Differential radiographic appearance of BRAF V600E-mutant metastatic colorectal cancer in patients matched by primary tumor location. J Natl Compr Cancer Netw. 2016;14(12):1536\u201343. https:\/\/doi.org\/10.6004\/jnccn.2016.0165.","journal-title":"J Natl Compr Cancer Netw"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-021-00793-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11523-021-00793-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-021-00793-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T11:51:32Z","timestamp":1614945092000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11523-021-00793-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,18]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["793"],"URL":"https:\/\/doi.org\/10.1007\/s11523-021-00793-7","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"type":"print","value":"1776-2596"},{"type":"electronic","value":"1776-260X"}],"subject":[],"published":{"date-parts":[[2021,2,18]]},"assertion":[{"value":"22 January 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Vanessa Wong\u2019s research institution, Walter and Eliza Hall Institute of Medical Research, is the recipient of research grant funding from Pierre-Fabre, Amgen, Novartis, Roche, and Merck, for unrelated projects. Peter Gibbs has received research grants from Pierre-Fabre, honoraria from Roche, and consulting fees and lecture payments from MSD, Merck and Amgen. Jayesh Desai has received research grants from Roche\/Genentech, Lilly, AstraZeneca, BeiGene, Novartis, Bristol Myers Squibb, and GlaxoSmithKline and consulting fees from Amgen, Pierre-Fabre, and BeiGene. Adnan Khattak, Brigette Ma, Jeanne Tie, Jeremy Shapiro, Louise Nott, Margaret Lee, Matthew Burge, Rachel Wong, Simone Steel, and Wei Hong have no conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}